- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Experienced pharma industry executive brings robust performance record to hospital specialty pharma company
BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced that it has strengthened its Management Board with the appointment of Pierre MORGON as Chief Operating Officer (COO).
Pierre A. MORGON, 45, PharmD, MS Law, MBA spent 23 years in the pharmaceutical industry in various positions involving P&L responsibility, large managerial scopes, staff and line accountability and international experience.
He joins from Schering-Plough France, where he managed the primary care operations in France for two years and the partnership with MSD. From 2004 to 2006, he was VP Hospital Operations at Bristol Myers Squibb. From 2003 to 2004, he served as General Manager of Yamanouchi Pharma France and prepared the merger with Fujisawa.
Prior to these positions in Operations, Pierre A. MORGON acquired a wide experience in spearheading the launch of products in hospital, retail and vaccine markets and in developing new business models. He served from 1998 to 2003 as VP International Marketing and VP Global Product Marketing at Aventis Pasteur. From 1993 to 1998, he was Marketing Director, USA-Canada-Japan at Synthelabo, successfully launching Ambien in the US and Kerlone in Japan and managing the joint venture with local partners. From 1988 to 1993, he served in Product and Group Product Management positions at Synthelabo and at ICI-Pharma.
Pierre A. MORGON is a member of the Management Centre Europe Sales & Marketing Council, and he is a lecturer in pharmaceutical industry seminars and in business schools. He received his Doctorate of Pharmacy from the University of Lyon in 1985, his Masters in Business Law from the Lyon Law School in 1986 and his MBA from ESSEC in Paris in 1998. He is also an alumnus of INSEAD, IMD and MCE executive programs.
Dr Dominique COSTANTINI, Co-Founder, President and CEO of BioAlliance Pharma and Dr Gilles AVENARD, Co-Founder and Chief Operating Officer, explained "As COO, Pierre MORGON will focus on the commercial operations across all territories and oversee the execution of the pricing and product launch strategy by the partners. He will drive the expansion into new countries, bring his expertise to the identification of additional business partners and contribute to the design of the company's strategy. Pierre will also contribute to the interface with the financial community. We are delighted to add Pierre to the Management Board and we are looking forward to this next phase of the development of BioAlliance."
About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc®) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg. The product has also completed a pivotal Phase III clinical trial in the United States in oropharyngeal candidiasis. The company is also performing a Phase III trial in labial herpes with acyclovir Lauriad® (which is based on the same Lauriad® muco-adhesive technology as Loramyc®, enabling targeted release at the disease site). BioAlliance Pharma also has a second technology (the Transdrug® nanoparticle technology, designed specifically for intracellular targeting) and, furthermore, is developing a new therapeutic entities program in oncology and infectious disease. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc®, with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with NovaMed). In May and August 2008, the company expanded its product portfolio by acquiring the Europe commercial rights to, respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from APR/Labtec.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).
For more information, please click here
BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
ATTOPSEMI Technology Joins FDXcelerator Program to Deliver Advanced Non-Volatile Memory IP to GLOBALFOUNDRIES 22 FDX® Technology Platform: Leading-edge I-fuse™ brings higher reliability, smaller cell size and ease of programmability for consumer, automotive, and IoT applications March 27th, 2017